Herantis Pharma’s clinical study with Lymfactin advances to high dose level

Herantis Pharma’s clinical study with Lymfactin advances to high dose level

Herantis Pharma Plc
Company release 6 March 2017 at 10:00 am

Herantis Pharma Plc’s (“Herantis”) clinical study with the company’s innovative gene therapy investigational product Lymfactin® for the treatment of secondary lymphedema has advanced to highest planned dose level owing to good reported safety. A Data Monitoring Committee of independent experts recommended proceeding to high dose treatments after assessing safety data on the previously treated patients. Following the recommendation, the first high dose treatment has already been administered.

 “We are naturally very happy for the safety of Lymfactin® in the first treatments”, comments Pekka Simula, Herantis’ CEO. “This is the first clinical study in the world to apply gene therapy for repairing damages of the lymphatic system. Safety of the patients is our #1 priority so we want to move ahead carefully. We are thrilled to announce this milestone by coincidence on March 6: World Lymphedema Day!”

“Collaboration with the participating university hospitals in this study has been excellent”, adds Katarina Jääskeläinen, Herantis’ Project Manager for the clinical study. “Secondary lymphedema is a disfiguring, disabling disease that severely impacts the quality of life of patients. We hope our Lymfactin® will significantly improve the quality of life of patients in the future.”

The Phase 1 clinical study continues recruiting patients with breast cancer associated lymphedema at three university hospitals in Finland: In Helsinki, Tampere, and Turku. The study intends to recruit at most 18 patients by the end of 2017.

Link to Press Release